![]() |
| Image Credit: Daisuke Ito (modified from Ito et al., JCI Insight, 2026 (CC BY 4.0) |
Scientific Frontline: Extended "At a Glance" Summary: PF-04457845 and ALS Progression
The Core Concept: Researchers have identified a metabolic marker in the blood, N-acyl taurines (NATs), that correlates with the progression of amyotrophic lateral sclerosis (ALS), and they found that a compound named PF-04457845, which boosts NAT levels, slows motor decline in mouse models of the disease.
Key Distinction/Mechanism: While most ALS research relies on mouse models mimicking inherited forms of the disease or patient-derived induced pluripotent stem (iPS) cells, this study began by analyzing the blood of human patients to identify metabolic changes across the body. The researchers discovered that PF-04457845 works by blocking an enzyme that breaks down NATs, thereby preserving higher levels of NATs, which appear to protect nerve cells and shift spinal cord immune cells (microglia) toward a supportive, anti-inflammatory state.
Origin/History: The study was conducted by a team led by Professor Masahisa Katsuno and Assistant Professor Daisuke Ito at Nagoya University Graduate School of Medicine, along with researchers from Aichi Medical University and Juntendo University. The findings were published in JCI Insight in 2026.
Major Frameworks/Components:
- Metabolite Screening: The team screened 867 metabolites in blood samples from patients with fast- and slow-progressing ALS, identifying NATs as a key marker.
- Endocannabinoid System: NATs are part of the extended endocannabinoid system. Elevated levels in fast-progressing ALS patients are thought to be a protective but ultimately insufficient response by the body.
- PF-04457845 Validation: The compound was tested on motor neurons derived from ALS patients' iPS cells, where it limited cellular damage, and in eight-week-old ALS mice, where it extended lifespans from 129.5 days to 138 days while improving strength and preserving nerve cells.






.jpg)





.png)
.png)


.jpg)
